Spero Therapeutics, Inc.

NASDAQ:SPRO

Biotechnology

Healthcare
$0.87 +3.79%

+$0.08 today

Market cap
$50.92M
Beta
1.46
P/E (TTM)
8.2
EPS (TTM)
$0.27
52W Low $1.80High $3.22

Volume 0.27M

Average 0.78M

SPRO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Spero Therapeutics, Inc.NASDAQ: SPRO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow outflow grows to $0

Q1 FY2026 financing cash flow was $0, compared with $0 a year earlier. Trailing-twelve-month financing cash flow was $0.

Context

  • Financing cash flow amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Financing cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly financing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Financing Cash Flow vs competitors

How SPRO compares with its peers on the latest reported figures

  • SPRO's LTM Mar 2026 financing cash flow of $0 is the smallest of the 10 companies compared; the peer median is $35.04M.
  • Financing cash flow amounts to 0.0% of revenue for SPRO, versus a peer median of 477.0%.
SPRO Competitors Peer median
Financing Cash Flow for SPRO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$77.43M +29.1%——
IRDOpus Genetics, Inc.LTM Mar 2026$57.15M +156.6%+136.4%477.0%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$52.98M -17.1%-13.5%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$35.74M +16725.1%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026$35.04M +172.3%+87.5%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$27.62M —+7.0%—
ACTUActuate Therapeutics IncLTM Mar 2026$24.02M +4.3%+7.2%—
MCRBSeres Therapeutics, Inc.LTM Mar 2026$13.15M +112.2%-52.5%1146.1%
SEERSeer, Inc.LTM Mar 2026$11.67M -10.2%—77.6%
SPROSpero Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding SPRO) $35.04M+70.6%+7.1%477.0%

Competitors are the stored peer set for SPRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(89.76M)(46.42M)22.81M(68.57M)8.57M
Depreciation & Amortization1.12M869K367K2K0
Deferred Income Tax00000
Stock-Based Compensation9.43M9.12M7.93M7.79M4.33M
Change in Working Capital12.86M22.09M(70.38M)36.28M(27.16M)
Accounts Receivables3.83M1.55M(461K)(1.54M)3.06M
Inventory00000
Accounts Payables(53K)(484K)761K5.93M(6.61M)
Other Working Capital9.08M21.02M(70.68M)31.9M(23.6M)
Other Non-Cash Items11.43M6.61M6.28M1.04M1.64M
Operating Cash Flow(64.35M)(7.73M)(33M)(23.44M)(12.62M)
Capital Expenditures64.35M0000
Acquisitions (Net)39K0000
Purchases of Investments(43.92M)(26.97M)000
Sales of Investments51.55M60.78M000
Other Investing Activities00000
Investing Cash Flow7.67M33.81M000
Debt Repayment47.48M(54.49M)000
Common Stock Issued36.57M24.93M221K00
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00000
Financing Cash Flow84.05M(29.55M)221K00
Effect of Forex Changes(1)0000
Net Change in Cash27.38M(3.48M)(32.77M)(23.44M)(12.62M)
Free Cash Flow(64.35M)(7.73M)(33M)(23.44M)(12.62M)

Spero Therapeutics, Inc.

NASDAQ:SPRO

Intrinsic Alpha fair value

Locked

Current Price

$0.87

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.